The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2019
Filed:
Oct. 07, 2016
Alexandre Vasilievich Ivachtchenko, Hallandale, FL (US);
Andrey Alexandrovich Ivashchenko, Moscow, RU;
Nikolay Filippovich Savchuk, Rancho Santa Fe, CA (US);
Asavi, Llc, Hallandale, FL (US);
Alena Alexandrovna Ivachtchenko, Hallandale, FL (US);
Oleg Dmitrievich Mitkin, Khimki, RU;
Alexandre Vasilievich Ivachtchenko, Hallandale, FL (US);
Oleg Dmitrievich Mitkin, Khimki, RU;
Andrey Alexandrovich Ivashchenko, Moscow, RU;
Alena Alexandrovna Ivachtchenko, Hallandale, FL (US);
Nikolay Filippovich Savchuk, Rancho Santa Fe, CA (US);
Other;
Abstract
Nucleosides and nucleotides (nucleos(t)ides) have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with viral infections or cancer. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Therefore nucleos(t)ide are of great interest as promising chemotherapeutic agents, including: 2'-deoxy-L-uridine (CAS31501-19-6), 2′-deoxy-D-uridine (CAS951-78-0), telbivudine (CAS3424-98-4), zidovudine (AZT, CAS30516-87-1), trifluridine (CAS70-00-8), clevudine (CAS163252-36-6), PSI-6206 (CAS863329-66-2), 2′-(S)-2′-chloro-2′-deoxy-2′-fluorouridine (CAS1673560-41-2), ND06954 (CAS114248-23-6), stavudine (CAS3056-17-5), 5-ethynyltavudine (Festinavir, CAS634907-30-5), torcitabine (CAS40093-94-5), (−)-beta-D-(2R,4R)-dioxolane-thymine (DOT, 1-((2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-2,4(1H,3H)-pyrimidinedione, CAS No. 127658-07-5), 2-(6-amino-purin-9-yl)-ethanol (CAS707-99-3), 2′-C-methylcytidine (CAS20724-73-6), PSI-6130 (CAS817204-33-4), gemcitabine (CAS95058-81-4), 2′-chloro-2′-deoxy-2′-fluorocytidine (CAS1786426-19-4), 2′,2′-dichloro-2′-deoxycytidine (CAS1703785-65-2), 2′-C-methylcytidine (CAS20724-73-6), PSI-6130 (CAS817204-33-4), lamivudine (3TC, CAS134678-17-4), emtricitabine (CAS143491-57-0), 2′-deoxyadenosine (CAS958-09-8), 2′-deoxy-β-L-adenosine (CAS14365-45-8), 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine (CAS865363-93-5), didanosine (CAS69655-05-6), entecavir (CAS209216-23-9), FMCA (CAS1307273-70-6), dioxolane-G (DOG, CAS145514-01-8), β-D-2′-deoxy-2′-(R)-fluoro-2′-β-C-methylguanosine (CAS No 817204-45-8), abacavir (ABC, CAS136470-78-5), dioxolane-A (DOA, CAS #145514-02-9), [(2R,4R)-4-(6-cyclopropylamino-purin-9-yl)-[1,3]dioxolan-2-yl]-methanol (CAS1446751-04-7), amdoxovir (AMDX, CAS145514-04-1), (R)-1-(6-amino-purin-9-yl)-propan-2-ol (CAS14047-28-0), and [(2S,5R)-5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yl]-methanol. Macroheterocyclic nucleoside derivative and its analog of the general formula 1 or general formula 2, a stereoisomer, isotope-enriched analog, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein: wherein: Ris the substituent selected from H, F, Cl, CH, OH;